TABLE 4.

Activity of spiro-β-lactams against HIV-1.

Compound	CC50 μM	MPI (%) 25 μg/mL	IC50 HIV-1 μM	IC90 HIV-1 μM	Therapeutic index (CC50/IC50)
BSS-730A	76.84	99	0.014	0.025	5488.57
9a	215.46	0	Nd	Nd	Nd
9b	54.67	0	Nd	Nd	Nd
9c	58.13	0	Nd	Nd	Nd
9d	38.02	54	Nd	Nd	Nd
9e	60.29	44	Nd	Nd	Nd
9f	53.40	21	Nd	Nd	Nd
9g	45.28	0	Nd	Nd	Nd
9h	55.99	0	Nd	Nd	Nd
9i	35.78	100	0.015	0.020	2385.33
9j	60.03	93	0.089	0.209	674.49
9k	54.06	84	0.366	Nd	148.11
9l	55.83	100	0.111	0.221	502.97
9m	60.11	94	0.203	0.437	296.11
9n	62.29	100	0.017	0.046	3664.12
9o	44.74	0	Nd	Nd	Nd
12a	58.14	93	0.019	0.054	3060.00
12b	55.99	92	0.063	0.104	888.73
12c	55.02	87	0.050	0.116	1100.40
12d	53.00	80	0.178	0.413	297.75
12e	64.40	76	1.304	1.504	49.39
12f	70.14	88	0.132	0.585	531.34
12h	73.63	0	Nd	Nd	Nd
12i	78.30	87	0.140	0.223	559.29
13a	64.77	0	Nd	Nd	Nd
13b	63.68	0	Nd	Nd	Nd
13c	50.65	0	Nd	Nd	Nd
13d	73.79	0	Nd	Nd	Nd
13e	54.74	0	Nd	Nd	Nd
13f	58.75	0	Nd	Nd	Nd
13h	56.17	0	Nd	Nd	Nd
13i	61.21	0	Nd	Nd	Nd
14a	75.06	100	0.012	0.048	6255.00
14b	78.26	95	0.146	0.338	494.93
14c	77.61	100	0.015	0.018	5174.00
14d	133.60	100	0.015	0.019	8906.67
14e	100.10	94	0.211	0.720	474.41
14f	87.48	97	0.067	0.198	1305.67
14g	100.60	100	0.030	0.099	3353.33
14h	72.12	93	0.111	0.297	649.73
14i	66.87	95	0.143	0.305	467.62